Teknova Raised Its 2026 Revenue View to $45M-$47M-and Wants 2026 Free Cash Outflow Under $8M

Q2 results pushed Teknova's 2026 revenue target higher

Teknova set a higher bar for itself. After Q2 revenue of $12.2 million came in above the consensus estimate of $10.97 million, management raised 2026 revenue guidance to $45 million-$47 million from its prior $42 million-$44 million range. That mattered because consensus had been looking for about $43.82 million of full-year revenue, and estimates had already moved higher over the prior 90 days. One strong quarter did more than earn praise; it raised the benchmark for the rest of the year.

Improvement is visible, but the turnaround is not complete

Teknova still looks like an improving niche biotech supplier rather than a broken story. But this is not a clean turnaround yet. Adjusted EBITDA remained negative, which suggests the business is getting healthier without being fully healed. That is what makes the setup more interesting-and more risky. Expectations are higher now, so execution or valuation missteps could matter more. The main question is whether Teknova can keep converting better quarterly momentum into sustained improvement rather than just posting one strong quarter.